Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study of Pazopanib in Combination With Irinotecan and Temozolomide (PAZIT) for Children and Young Adults With Relapsed or Refractory Sarcoma

Next Previous
Trial Profile

Phase 1 Study of Pazopanib in Combination With Irinotecan and Temozolomide (PAZIT) for Children and Young Adults With Relapsed or Refractory Sarcoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Irinotecan (Primary) ; Pazopanib (Primary) ; Temozolomide (Primary)
  • Indications Ewing's sarcoma; Osteosarcoma; Primitive neuroectodermal tumours; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Adverse reactions
  • Acronyms PAZIT

    • Most Recent Events

    • 30 Dec 2020 Status changed from active, no longer recruiting to completed.
    • 31 May 2020 The protocol was amended to the dose escalation plan and patients received fixed doses of pazopanib PO (225 mg/m2/dose) and reduced irinotecan doses (IV 25-37.5 or PO 45-67.5 mg/m2/dose) and temozolomide PO 100 mg/m2/dose on Days 1-5, as per the results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top